Advancing patient care through the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR)

Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR)

Research output: Contribution to journalArticle

Abstract

Recent advances in rare disease research are accelerated by the work of consortia that have been supported by the National Institutes of Health. Development of such consortia rely on multidisciplinary relationships and engagement with patient advocacy groups, as well as the National Institutes of Health and industry and academic partners. In this rostrum we present the development of such a process that focuses on eosinophilic gastrointestinal diseases. Principal investigators, patient advocacy groups, research assistants, and trainees work together to perform natural history studies that promote clinical trial readiness tools, conduct clinical trials, train a new generation of investigators, and perform innovative pilot studies.

Original languageEnglish (US)
Pages (from-to)28-37
Number of pages10
JournalJournal of Allergy and Clinical Immunology
Volume145
Issue number1
DOIs
StatePublished - Jan 2020

Fingerprint

Patient Advocacy
Gastrointestinal Diseases
National Institutes of Health (U.S.)
Patient Care
Research Personnel
Clinical Trials
Rare Diseases
Natural History
Research
Industry

Keywords

  • Eosinophils
  • advocacy
  • allergy
  • consortium
  • esophagitis
  • gastrointestinal

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR). / Advancing patient care through the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR). In: Journal of Allergy and Clinical Immunology. 2020 ; Vol. 145, No. 1. pp. 28-37.
@article{0e76759825864c9fa90f6ba721c2e5b0,
title = "Advancing patient care through the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR)",
abstract = "Recent advances in rare disease research are accelerated by the work of consortia that have been supported by the National Institutes of Health. Development of such consortia rely on multidisciplinary relationships and engagement with patient advocacy groups, as well as the National Institutes of Health and industry and academic partners. In this rostrum we present the development of such a process that focuses on eosinophilic gastrointestinal diseases. Principal investigators, patient advocacy groups, research assistants, and trainees work together to perform natural history studies that promote clinical trial readiness tools, conduct clinical trials, train a new generation of investigators, and perform innovative pilot studies.",
keywords = "Eosinophils, advocacy, allergy, consortium, esophagitis, gastrointestinal",
author = "{Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR)} and Seema Aceves and Collins, {Margaret H.} and Rothenberg, {Marc E.} and Furuta, {Glenn T.} and Nirmala Gonsalves and Abonia, {J. Pablo} and Samuel Almonte and Rachel Andrews and Ashley Arrington and Nicoleta Arva and Fred Atkins and Dominique Bailey and Alexis Berry and Bridget Besl and Scott Bolton and Peter Bonis and Wendy Book and Kimberly Bray and Teresa Brown and Cassandra Burger and Deirdre Burke and Jonathon Cahoon and Kelley Capocelli and Mirna Chehade and Margaret Collins and Carla Davis and Evan Dellon and Maureen DeMarshall and Lauren DiTommaso and Ranjan Dohil and Michael Eby and Gary Falk and David Fleischer and Heather Foote and Kelci Foss and Joel Friedlander and Patricia Fulkerson and Glenn Furuta and Debra Geno and Thomas Greuter and Sandeep Gupta and Frank Hamilton and Kirk Harris and Jennifer Harris and Ikuo Hirano and Girish Hiremath and Nicole Holland-Thomas and Lea Jacinto and Amir Kagalwalla and Timothy Kaseta",
year = "2020",
month = "1",
doi = "10.1016/j.jaci.2019.11.012",
language = "English (US)",
volume = "145",
pages = "28--37",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",
number = "1",

}

Advancing patient care through the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR). / Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR).

In: Journal of Allergy and Clinical Immunology, Vol. 145, No. 1, 01.2020, p. 28-37.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Advancing patient care through the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR)

AU - Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR)

AU - Aceves, Seema

AU - Collins, Margaret H.

AU - Rothenberg, Marc E.

AU - Furuta, Glenn T.

AU - Gonsalves, Nirmala

AU - Abonia, J. Pablo

AU - Almonte, Samuel

AU - Andrews, Rachel

AU - Arrington, Ashley

AU - Arva, Nicoleta

AU - Atkins, Fred

AU - Bailey, Dominique

AU - Berry, Alexis

AU - Besl, Bridget

AU - Bolton, Scott

AU - Bonis, Peter

AU - Book, Wendy

AU - Bray, Kimberly

AU - Brown, Teresa

AU - Burger, Cassandra

AU - Burke, Deirdre

AU - Cahoon, Jonathon

AU - Capocelli, Kelley

AU - Chehade, Mirna

AU - Collins, Margaret

AU - Davis, Carla

AU - Dellon, Evan

AU - DeMarshall, Maureen

AU - DiTommaso, Lauren

AU - Dohil, Ranjan

AU - Eby, Michael

AU - Falk, Gary

AU - Fleischer, David

AU - Foote, Heather

AU - Foss, Kelci

AU - Friedlander, Joel

AU - Fulkerson, Patricia

AU - Furuta, Glenn

AU - Geno, Debra

AU - Greuter, Thomas

AU - Gupta, Sandeep

AU - Hamilton, Frank

AU - Harris, Kirk

AU - Harris, Jennifer

AU - Hirano, Ikuo

AU - Hiremath, Girish

AU - Holland-Thomas, Nicole

AU - Jacinto, Lea

AU - Kagalwalla, Amir

AU - Kaseta, Timothy

PY - 2020/1

Y1 - 2020/1

N2 - Recent advances in rare disease research are accelerated by the work of consortia that have been supported by the National Institutes of Health. Development of such consortia rely on multidisciplinary relationships and engagement with patient advocacy groups, as well as the National Institutes of Health and industry and academic partners. In this rostrum we present the development of such a process that focuses on eosinophilic gastrointestinal diseases. Principal investigators, patient advocacy groups, research assistants, and trainees work together to perform natural history studies that promote clinical trial readiness tools, conduct clinical trials, train a new generation of investigators, and perform innovative pilot studies.

AB - Recent advances in rare disease research are accelerated by the work of consortia that have been supported by the National Institutes of Health. Development of such consortia rely on multidisciplinary relationships and engagement with patient advocacy groups, as well as the National Institutes of Health and industry and academic partners. In this rostrum we present the development of such a process that focuses on eosinophilic gastrointestinal diseases. Principal investigators, patient advocacy groups, research assistants, and trainees work together to perform natural history studies that promote clinical trial readiness tools, conduct clinical trials, train a new generation of investigators, and perform innovative pilot studies.

KW - Eosinophils

KW - advocacy

KW - allergy

KW - consortium

KW - esophagitis

KW - gastrointestinal

UR - http://www.scopus.com/inward/record.url?scp=85076865962&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85076865962&partnerID=8YFLogxK

U2 - 10.1016/j.jaci.2019.11.012

DO - 10.1016/j.jaci.2019.11.012

M3 - Article

C2 - 31758958

AN - SCOPUS:85076865962

VL - 145

SP - 28

EP - 37

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 1

ER -